Xenikos B.V focused on the development of innovative immunotherapies for the treatment of patients suffering from serious immune diseases or rejection after transplantation,
GE Healthcare’s Life Sciences business and Valneva SE, a fully integrated vaccine biotech company, are sharing the results of a successful collaboration to optimize virus productivity in Valneva’s EB66® cell-line, a proprietary technology for the production of a wide variety of vaccines, including human and animal health vaccines.
Breckenridge Pharmaceutical, Inc. announced the immediate launch of Methylergonovine Maleate Injection, USP 0.2mg/mL. This product is an AP rated generic to Methergine®, a product owned by Edison Therapeutics, LLC. and is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage.